Aqualung Therapeutics Corporation is a Tucson-based early-stage biotech company whose leadership are experienced life science executives and entrepreneurs with expertise in Precision Medicine, Drug Development, Drug Manufacturing and Commercialization. They are committed to exploring NAMPT as a key target and novel diagnostic to address the “unchecked inflammation” elicited by dysregulated innate immunity pathways in a variety of acute and chronic conditions with significant unmet therapeutic needs.